Form 4: Ionis Pharmaceuticals Executive Granted Stock Options

C. Frank Bennett, EVP and Chief Scientific Officer at Ionis Pharmaceuticals, was granted 22,000 stock options on January 2, 2025.

Summary

• C. Frank Bennett, the Executive Vice President and Chief Scientific Officer of Ionis Pharmaceuticals, received 22,000 non-qualified stock options.
• The options were granted on January 2, 2025, with an exercise price of $34.69 per share.
• The options vest over a period of four years, with 25% vesting on January 2, 2026, and the remaining 75% vesting in 36 equal monthly installments thereafter.
• The options expire on January 1, 2035.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation event, which is generally positive for aligning management and shareholder interests. There are no indications of negative sentiment.

Positives

• The granting of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Risks

• The value of the stock options is dependent on the future performance of Ionis Pharmaceuticals' stock price.
• There is a risk that the stock price may not reach a level that makes exercising the options profitable for the executive.

Future Outlook

The stock options will vest over the next four years, incentivizing the executive to contribute to the company's long-term success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry, similar to companies like Alnylam Pharmaceuticals and Biogen.
• The vesting schedule of 25% after one year and the remainder over three years is also typical for such grants.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns management's interests with the company's long-term performance.
• The executive is incentivized to increase the company's value to benefit from the stock options.

Key Dates

Keywords

stock options, executive compensation, insider trading, Ionis Pharmaceuticals, IONS, C. Frank Bennett, equity incentive plan